Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Anetumab ravtansine (Primary) ; Cisplatin; Gemcitabine
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms ARCS-Multi
- Sponsors Bayer
- 15 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer.
- 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.
- 01 Sep 2017 According to a Bayer media release, data from this trial will be presented at the European Society for Medical Oncology (ESMO) Congress in Sep 2017.